Participated · Series B · Apr 2022

RVAC Medicines is an mRNA platform company incubated by CBC and headquartered in Singapore, building a pipeline of novel mRNA vaccines and therapeutics targeting infectious diseases, autoimmune diseases, and cancers. The company aims to develop a multivalent COVID vaccine and other mRNA innovations, with COVID candidates shown safe and efficacious in preclinical studies and planned to enter clinical studies in Q3 2022. RVAC leverages a strategic partnership with Acuitas Therapeutics for lipid nanoparticle delivery and is supported by a world-class scientific advisory board. Proceeds from its recent financing will fund preclinical and clinical development and the buildout of R&D and manufacturing capabilities. RVAC currently maintains R&D centers in Boston and Shanghai and plans new R&D and manufacturing facilities in Singapore and China, with initiatives expected to create over 100 jobs in Singapore. Since its inception in June 2021, the company has raised a total of US$140 million.

Participated · Series C · Feb 2022

Biorchestra is an RNA therapeutics company based in Daejeon, South Korea, and Cambridge, Massachusetts. It develops RNA-based therapeutics using a BMD platform that can control microRNAs which regulate multiple messenger RNAs involved in disease. The company has developed a proprietary drug delivery system (BDDS™) for commercial drug development and reports IV-delivered ASO knock-down efficacy in cortex, hippocampus, striatum and spinal cord. Leadership includes CEO Branden (Jinhyeob) Ryu, CMO and US President Dr. Louis O’Dea, and CFO Young-Gil Kim. Biorchestra plans to use new funding to expand R&D and its product pipeline, complete a GMP facility, and initiate nonclinical toxicology programs. The company raised $45M in Series C financing to support these activities.

Participated · Equity · Apr 2021

한국신용데이터 provides payment rails and POS solutions targeted at small-business owners and has built capabilities considered essential for its merchant customers. Over the past two years the company steadily raised more than ₩2,000억 and completed a Series D totaling ₩2,400억. Management says it invested aggressively in payment infrastructure, POS solutions, and talent acquisition, expanding headcount by more than 2x. Those moves supported rapid commercial growth: the company reports growing revenue more than 20-fold. The firm emphasizes continued customer focus and cautious execution, noting plans to keep helping merchant customers through the coming second half. The company framed its fundraising and operational choices as deliberate investments made while other firms pulled back. Korea Credit Data offers a bookkeeping super app for small and mid-sized enterprises called Cash Note (launched 2017) that aggregates cash flow, credit card sales, expenditure, sales ledgers and policy information. The company has added SME-focused lending services that connect merchants to working capital loan programs. KCD claims more than 1.7 million registered merchants and has grown its app into a widely used platform among small business owners. The startup has made strategic acquisitions including ImU (POS) and Persona (government subsidy alerts), and it has announced the acquisition of Fiserv Korea as part of a partnership. KCD plans to use the new capital to expand its 230-person team and pursue additional acquisitions. Financially, the company has raised about $112 million since its 2016 founding and its Series D has reached roughly $70 million after the latest extension, valuing the business at about $776 million. Korea Credit Data Co., Ltd. announced a KRW 40,000,000,000 funding round that closed on April 20, 2021. The transaction included participation from Pavilion Capital Pte. Ltd., KB Financial Group, GS Holdings, Kakao Ventures, and KT Investment. Pavilion Capital invested $20,000,000 (KRW 22,345,400,000) as part of the round. The company has raised KRW 60,000,000,000 in total to date. Post-closing, the enterprise value of the company exceeded KRW 400,000,000,000.